Quantum Leap

For biotechnology and life sciences organizations working at the front end of drug discovery, access to meaningful R&D funding and industry collaboration can make the difference between a promising concept and real-world impact. The Quantum Leap program, delivered by the Quebec Consortium for Drug Discovery (CQDM), is designed to help innovative SMEs, nonprofits, and research centres push forward new technologies that can significantly improve how drugs are discovered and developed. The focus is on translational research that moves beyond theory, supporting tools, platforms, and therapeutic approaches with clear potential for industry adoption.

Quantum Leap is particularly attractive for Quebec-based life sciences organizations developing enabling technologies that address bottlenecks across the drug development pipeline, from early discovery to preclinical validation. Projects are carried out in close collaboration with large biopharmaceutical companies, giving funded teams direct access to industry expertise and future partnership opportunities. Funding support can be substantial, often ranging from several hundred thousand dollars to well over one million dollars per project, provided as non-repayable contributions and typically structured as part of a broader, co-funded research effort.

With projects running over multiple years and an emphasis on tangible deliverables for pharmaceutical partners, Quantum Leap is well suited to organizations aiming to validate, scale, or industrialize their innovations. For businesses and research groups looking to understand how their R&D roadmap might align with CQDM’s priorities, exploring the full program details can clarify whether this opportunity is the right strategic fit.